Proposal to list orthopaedic implants supplied by Ossis Limited
What we’re proposing
PHARMAC is seeking feedback on a proposal to list a range of custom designed orthopaedic implants and associated implant design services (“Orthopaedic Products”) in Part III of Section H of the Pharmaceutical Schedule from 1 November 2018, through a provisional agreement with Ossis Limited (“Ossis”).
What would the effect be?
From 1 November 2018 Ossis’ range of orthopaedic products would be listed under the proposed national agreement for all DHBs to purchase under, subject to consultation and approval by PHARMAC’s Board or delegate (“Agreement”).
This Agreement would not be for sole supply, with DHBs continuing to be able to purchase orthopaedic products from other suppliers.
The Agreement would supersede any existing DHB contracts with Ossis for the devices included in the Agreement. Any Orthopaedic Product listed in the Agreement and purchased by a DHB would be at the price, terms and conditions stated in the Agreement, effective from the date of listing on the Pharmaceutical Schedule.
As part of the Agreement Ossis would provide educational services that would be tailored to the individual needs of DHBs, in formats and at times as required by DHBs.
Pricing for the orthopaedic products in the Agreement, subject to any prior termination of the Agreement, would not be increased without prior approval by PHARMAC.
Who we think will be interested
- DHB Staff
- Orthopaedic Surgeons
- Theatre and Sterile Services personnel
- Other perioperative personnel
- Procurement and supply chain personnel
- Radiology personnel
About the medical devices
The orthopaedic products under this agreement are patient customised implants used to treat bone related injury or disease through surgical intervention, and the Agreement covers services relating to the design of the implants.
Why we’re proposing this
This RFP was for non-exclusive national agreements for listing in the Pharmaceutical Schedule.
PHARMAC has been working with suppliers who responded to the RFP to seek provisional agreements and this proposal is the latest to arise from this processes. We expect to consult on further proposed agreements in this category over the coming months.
Details about our proposal
PHARMAC has entered into a provisional agreement with Ossis for the design and supply of their AceOs branded patient customised orthopaedic implants.
Pricing has been made available to appropriate DHB personnel.
This proposal would result in Pharmaceutical Schedule listings for five products in the Orthopaedic Products category.
To provide feedback
Send us an email: firstname.lastname@example.org by 4pm on Thursday, 4 October 2018.
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.